麻豆传媒

Ponatinib-blinatumomab led to durable remissions without transplant in most, but 13% relapsed

But no overall survival benefit seen in confirmatory trial

Top news in 2024 included the first CAR-T approval for CLL, triplet regimens, and more

AMPLIFY trial paves the way for FDA approval of acalabrutinib plus venetoclax

Complete responses seen in 43% of patients in expansion cohort of EPCORE CLL-1 study

Cytokine release syndrome developed in all patients, including grade 3/4 events in nearly half

Blinatumomab consolidation reduced risk of relapse by 61% versus chemotherapy alone

Little is being done to curb the risk

All drugs except one remained more expensive in the U.S.

Results of FELIX study supported obecabtagene autoleucel's recent FDA approval

Agency is evaluating the need for further regulatory action

News, features, and commentary about cancer-related issues

Benefit shown in trial of patients flagged for high risk of cardiotoxicity

Complete responses in 21% of patients treated with single-agent revumenib